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Activation of Carboplatin by Carbonate
Anthony J. Di Pasqua,† Jerry Goodisman,† Deborah J. Kerwood,† Bonnie B. Toms,‡
Ronald L. Dubowy,‡ and James C. Dabrowiak*,†
Department of Chemistry, Syracuse UniVersity, 111 College Place, CST, Room 1-014,
Syracuse, New York 13244-4100, and Department of Pediatrics, Upstate Medical UniVersity, State UniVersity of
New York, 750 East Adams Street, Syracuse, New York 13210
ReceiVed September 16, 2005

Carboplatin, [Pt(NH3)2(CBDCA-O,O′)], 1, where CBDCA is cyclobutane-1,1-dicarboxylate, is in wide
clinical use for the treatment of ovarian, lung, and other types of cancer. Because carboplatin is relatively
unreactive toward nucleophiles, an important question concerning the drug is the mechanism by which
it is activated in vivo. Using [1H,15N] heteronuclear single quantum coherance spectroscopy (HSQC)
NMR and 15N-labeled carboplatin, we show that carboplatin reacts with carbonate ion in carbonate buffer
to produce ring-opened products, the nature of which depends on the pH of the medium. The assignment
of HSQC NMR resonances was facilitated by studying the reaction of carboplatin in strong acid, which
also produces a ring-opened product. The HSQC NMR spectra and UV-visible difference spectra show
that reaction of carboplatin with carbonate at pH > 8.6 produces mainly cis-[Pt(NH3)2(CO3-2)(CBDCAO)]-2, 5, which contains the mono-dentate CBDCA ligand and mono-dentate carbonate. At pH 6.7, the
primary product is the corresponding bicarbonato complex, which may be in equilibrium with its
decarboxylated hydroxo analogue. The UV-visible absorption data indicate that the pKb for the protonation
of 5 is ∼8.6. Thus, the reaction of carboplatin with carbonate produces a mixture of ring-opened species
that are anions at physiological pH. HSQC NMR studies on 15N-labeled carboplatin in RPMI culture
media containing 10% fetal bovine serum with and without added carbonate suggest that carbonate is
the attacking nucleophile in culture media. However, because the rate of reaction of carbonate with
carboplatin at physiological pH is small, NMR peaks for ring-opened carboplatin were not detected with
HSQC NMR. The rate of disappearance of carboplatin in culture medium containing 9 × 108 Jurkat
cells is essentially the same as that in carbonate buffer, indicating that the ring-opening reaction is not
affected by the presence of cells. This work shows that carbonate at concentrations found in culture
media, blood, and the cytosol readily displaces one arm of the CBDCA ligand of carboplatin to give a
ring-opened product, which at physiological pH is a mixture of anions. These ring-opened species may
be important in the uptake, antitumor properties, and toxicity of carboplatin.
Introduction
Carboplatin, [Pt(NH3)2(CBDCA-O,O′)]1 (1 in Figure 1),
where CBDCA is cyclobutane-1,1-dicarboxylate, is a secondgeneration Pt2+ anticancer drug, which is less oto- and nephrotoxic than cis-diamminedichloroplatinum(II) (cisplatin), 2 (1,
2). Both cisplatin and carboplatin have cis ammonia ligands,
but in the latter, the two chloride ligands of cisplatin are replaced
by a dicarboxylate chelate ring (Figure 1). Because a bidentate
chelate ring is difficult to displace in substitution reactions (3),
carboplatin is much less reactive than cisplatin. Studies show
that the rate constant for the reaction of carboplatin with water
is very small, k1 < 10-8 s-1 (4), which likely precludes
hydrolysis as a means of activating the drug in vivo.
In exploring ways to displace the chelate ring of carboplatin,
Sheldrick and co-workers (5) used HPLC, NMR, and capillary
* To whom correspondence should be addressed. Tel: 315-443-4601.
Fax: 315-443-4070. E-mail: jcdabrow@syr.edu.
† Syracuse University.
‡ State University of New York.
1 Abbreviations: carboplatin, cis-diammine(cyclobutane-1,1-dicarboxylato)platinum(II) Pt(NH3)2(CBDCA-O,O′); CBDCA, cyclobutane-1,1-dicarboxylate; H2CBCDA, cyclobutane-1,1-dicarboxylic acid; cisplatin, cisdiamminedichloroplatinum(II); dH2O, distilled deionized water; D2O,
deuterium oxide; FBS, fetal bovine serum; Pt, platinum; HSQC, heteronuclear single quantum coherance spectroscopy.

Figure 1. Structures of carboplatin and cisplatin.

electrophoresis-mass spectrometry to show that the thioether
group in a tripeptide can displace the bidentate dicarboxylate
of carboplatin. The introduction of the thioether into the
coordination sphere of the platinum (Pt) ion labilized the
ammonia molecule trans to the thioether, which ultimately led
to the replacement of all of the ligands of carboplatin with
donors from the peptide. Sadler and co-workers (6) showed that
the reaction of carboplatin with methionine is rapid (k ) 2.7 ×
10-3 M-1 s-1) and that it produces a stable ring-opened species,
cis-[Pt(CBDCA-O)(NH3)2(L-HMet-S)], which has a long halflife. The authors suggested that this reaction may play a role in
the biological activity of carboplatin. While a thioether group
can readily displace the bidentate chelate ring of carboplatin,
the resulting Pt-methionine adduct is thermodynamically stable
making transfer of the Pt to a target via breakage of the Pt-S
bond difficult (3). For example, a cis-(NH3)2Pt(II) moiety, which
is bound to the terminal Met1 of ubiquitin, cannot be transferred
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to a potential DNA target, 5′-GMP (7). However, for certain
structures containing both a thioether group and a DNA base,
the initially formed Pt-S adduct can rearrange to the Pt-base
adduct, suggesting that reaction of carboplatin with a thioether
may be a means of activating the drug in vivo (8).
In an effort to show that carboplatin may not require
activation, Sadler and co-workers (9) used NMR to measure
the rate of reaction of the drug with 5′-GMP. They found that
carboplatin slowly reacts with the nucleotide, t1/2 ∼ 46 h, to
produce cis-[Pt(NH3)2(CBDCA-O)(5′-GMP)], suggesting that
the drug could directly attack DNA in vivo.
Carbonate is an important ligand for the uptake and toxicity
of Cd2+, Pb2+, and Ti4+ (10-12), and it may play a role in the
biological activity of Pt antitumor agents. Carbonate, which is
in equilibrium with bicarbonate, carbonic acid, and dissolved
carbon dioxide (13), is ubiquitous in biological systems, and it
is found in high concentration (∼24 mM) in blood (14). Metal
complexes having bound carbonate (carbonato complexes) can
be made by ligand displacement reactions involving carbonate
ion, or they can be formed by the rapid addition of carbon
dioxide to a metal-bound hydroxide ligand (15, 16).
The potential of carbonate as an activating ligand for Pt was
explored by Chaney and co-workers (17) who demonstrated that
a six-membered malonate chelate ring bound to Pt2+ could be
readily displaced in carbonate buffer. Because the resulting
carbonato complex was unstable, the authors suggested that
bicarbonate/carbonate ion may be a nonenzymatic pathway for
the formation of biologically active Pt complexes.
Earlier, we used [1H,15N] heteronuclear single quantum
coherance spectroscopy (HSQC) NMR and 15N-labeled cisplatin
to show that a metabolite of the drug that forms in RPMI culture
medium is rapidly taken up and/or modified by Jurkat leukemia
cells (18). Further investigation by us using one-dimensional
and two-dimensional NMR and UV-vis absorption spectroscopy
revealed that the metabolite is a Pt carbonato complex (19),
which is formed when cisplatin aquates in a medium containing
carbonate.
In this report, we use 15N-labeled carboplatin, [1H,15N] HSQC
NMR, and UV-vis spectroscopy to show that carbonate ion in
carbonate buffer readily displaces the CBDCA chelate ring of
carboplatin to give a complex having mono-dentate carbonate
and the mono-dentate CBDCA ligand. The compound is
characterized from its HSQC NMR chemical shift data and by
comparison of the corresponding aquo complex produced in the
acid hydrolysis of carboplatin. Studies done in the pH range
from 6.7 to 9.3 show that the mono-carbonato compound is in
a proton equilibrium with its bicarbonate form and possibly its
decarboxylated hydroxo form. In all studies, therapeutically
relevant carboplatin concentrations were used.
The ability of carbonate to react with carboplatin in culture
media is examined by measuring the rate of disappearance of
15N-labeled carboplatin using [1H,15N] HSQC NMR. Although
the amount of ring-opened product produced in culture media
is too small to be detected with HSQC NMR, the rate of
disappearance of 1 is dependent on the presence of carbonate
in the medium, suggesting that carbonate ion is the attacking
nucleophile under these conditions as well. Studies done in the
presence of Jurkat cells show that the rate of disappearance of
1 is not affected by cells in the medium. Because carboplatin
reacts with carbonate in culture media, a carboplatin-carbonato
complex may also be present in the blood of patients receiving
the drug. To the extent that speciation in blood is important for
biodistribution, carbonato complexes may play a role in the
uptake, antitumor properties, and toxicity of carboplatin.
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Materials and Methods
Materials. K2PtCl4, H2CBDCA, and 15NH4Cl used in the
synthesis of 15N-labeled carboplatin were purchased from SigmaAldrich (St. Louis, MO). The NaHCO3 (>99%) was from SigmaAldrich, and the fetal bovine serum (FBS) and RPMI-1640 with
(15-040) and without (50-020) NaHCO3 were from Mediatech
(Herndon, VA). The HClO4 (60%) and deuterium oxide (D2O)
(99.9%) were purchased from Fisher Scientific (Pittsburgh, PA)
and Sigma-Aldrich, respectively, and used without purification.
Synthesis of 15N-Carboplatin. To a solution containing 0.659
g (1.36 mmol) of cis-Pt(15NH3)2I2 (20) in 5 mL of distilled deionized
water (dH2O) was added 5 mL of a solution containing 0.485 g
(2.85 mmol) of silver nitrate in 5 mL of dH2O. The resulting
solution was stirred overnight in the dark after which time the AgI
that formed was removed by filtration through diatomaceous earth.
To the filtrate was added 0.215 g (1.50 mmol) of 1,1-cyclobutanedicarboxylic acid, and the pH of the resulting solution was adjusted
to 5.0 using 10 M KOH. After it was stirred for 3 h, the solvent
was removed in a vacuum (∼30 °C) and the white solid was washed
with 5 mL of cold water, ethanol, and ether and dried to yield 27.8%
based on cis-Pt(15NH3)2I2. The 1H NMR spectrum of 15N-carboplatin
in D2O [referenced internally to, DSS, Me3Si(CH2)3SO3Na] at 25
°C, pH 5.0, exhibits signals at 2.880 (triplet, 4H, 3JH-H ) 8.0 Hz)
and 1.895 (quintet, 2H, 3JH-H ) 8.0 Hz) (4, 9).
[1H,15N] HSQC NMR Spectroscopy. HSQC NMR spectra were
recorded on a Bruker Advance 500 MHz NMR equipped with a 5
mm triple axis probe in the earlier described manner (18). Each
kinetic run consisted of successive NMR measurements (each 60
min in length, ns ) 48). Peak volumes in arbitrary units for all
peaks of appreciable intensity, excluding 195Pt satellites, were
calculated using Bruker software. The 15N chemical shifts were
referenced externally to 1 M (15NH4)2SO4 in 95/5 H2O/D2O, which
was acidified to pH ∼ 1 by the addition of H2SO4. The 1H chemical
shifts were referenced externally to Me3SiCD2CD2CO2Na, TSP, in
a pH 7.15, 23 mM sodium carbonate buffer.
Spectra were recorded in 95/5 H2O/D2O at 37 °C. Freshly
prepared stock solutions of the labeled drug in water were prepared,
and appropriate volumes were added to solutions to give a final
concentration of drug of 110 µM in a final volume of 920 µL. The
pH 8.6, 23.8 mM and pH 8.6, 10 mM carbonate buffers were
prepared by dissolving the appropriate amount of NaHCO3 in water.
The pH 7.5, 23.8 mM and pH 7.5, 10 mM carbonate buffers as
well as the pH 6.7, 23.8 mM and pH 6.7, 10 mM carbonate buffers
were prepared in the identical manner with the addition of the
appropriate amount of 3 N HClO4. The “normal medium” used in
the NMR studies was RPMI-1640 (pH 7.2) plus 10% FBS. To this
was also added 100 µg/mL streptomycin, 100 IU/mL penicillin,
and 2.0 mM S-glutamine. The pH of the “medium without
carbonate”, RPMI (50-020), 10% FBS, 100 µg/mL streptomycin,
100 IU/mL penicillin, and 2.0 mM S-glutamine, was adjusted to
pH 7.5 by addition of 3 N perchloric acid. Studies were also done
with “FBS alone”, which were done in 95/5 H2O/D2O containing
10% FBS, pH 7.5.
UV-Visible Absorption Spectroscopy. The UV-vis absorption
spectra at 37 °C were obtained using a Cary 50 spectrophotometer
equipped with a thermostated cell holder in a 1 cm path length
cell. Absorption spectra were collected every hour for 30 h in the
wavelength range of 500-190 nm, using a scan rate of 60 nm/
min. Difference spectra were obtained by subtracting the spectrum
immediately after addition of 1 to the buffer (t ) 0 spectrum) from
spectra taken at various times. Each difference spectrum was fitted
to a sum of Gaussians using PeakFit (v. 4) to give band positions
and areas. The area of a particular band (identified by position)
was then plotted vs time.
Cell Studies. Carboplatin (58 µL from a 37.8 mM stock solution
of 1 in water) was added to 20 mL of medium (RPMI + 10%
FBS, 100 µg/mL streptomycin, 100 IU/mL penicillin, and 2.0 mM
S-glutamine) containing 900 million Jurkat cells to give a final
concentration of 110 µM 1 in the culture medium. The cells were
kept under standard conditions in a humidified, 37 °C, 5% CO2

Carboplatin Carbonato Complexes
Scheme 1. Ring Opening of Carboplatin in Acid
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Table 1. 1H and

15N Chemical Shifts of the Ammine Ligands in
cis-Diammine Pt(II) Complexes

complex
Pt(NH3)2(CBDCA-O,O′) (1)
[Pt(NH3)2(CBDCA-O)(H2O)]+ (3)
[Pt(NH3)2(H2O)2]+2 (4)
[Pt(NH3)2(CBDCA-O)(CO3)]-2 (5)a,b
[Pt(NH3)2(CBDCA-O)Cl]- c
[Pt(NH3)2(CBDCA-O)(HPO4)]d

incubator. At various times, a 916 µL aliquot of cells plus medium
was removed from the incubation flask and the cells were separated
from the medium by centrifugation (1400g). To the medium
supernatants, volume ∼ 875 µL, was added ∼45 µL of D2O to
give a final volume of 920 µL. The solution, referred to as “medium
exposed to Jurkat cells,” was placed in a capped 5 mm NMR tube,
and an 1H-15N HSQC NMR spectrum of the sample was obtained.
The elapsed time from the point of removal of the aliquot from the
incubation flask to the end of the NMR data collection time
(duration, 0.5 h) for each time point was e0.8 h. Cell viabilities
were measured by light microscopy, using a hemacytometer under
standard trypan blue conditions (21). Cell viabilities taken at 0, 6,
and 25 h after addition of drug were 96.9, 96.9, and 0%,
respectively.
Acid Hydrolysis of Carboplatin. Freshly prepared stock solutions of labeled 1 in water were prepared, and appropriate volumes
were added to a solution of 95/5 H2O/D2O to give a final
concentration of 220 µM carboplatin in a final volume of 920 µL.
The solution was acidified by the addition of HClO4 to give a
hydrogen ion concentration of 0.03 M, and [1H,15N] HSQC NMR
spectra, at 37 °C, were obtained approximately every 0.33 h. At
1.8 h after the addition of acid (t ) 1.8 h), the pH of the solution
was adjusted to ∼2.2 by the addition of 10 M KOH, and further
HSQC NMR spectra were obtained at 0.33 h intervals out to t )
3.3 h. Assuming that peak intensities were proportional to concentrations and knowing that the sum of the concentrations of the three
species observed was 220 µM, we derived the species concentrations
at each time point, before and after the addition of KOH.

Results
Ring Opening of Carboplatin. [1H,15N] HSQC NMR. The
hydrolysis of carboplatin in acid, Scheme 1, was followed using
[1H,15N] HSQC NMR (22). Allowing 1 to stand in 0.03 M
HClO4 at 37 °C resulted in a decrease in the HSQC NMR
intensity for peak 1 (at 1H,15N, δ ) 4.17/-81.3) and the
appearance of two new peaks at 4.26/-82.3 and 4.31/-87.8
(Table 1). At later times, an additional peak at 4.50/-86.5 was
also observed in the spectra. The [1H,15N] HSCQ NMR spectrum
1.3 h after addition of acid is shown in Figure 2a. Because the
peaks at 4.26/-82.3 and 4.31/-87.8 increase in intensity at the
same rate, they have been assigned to the ring-opened product,
cis-[Pt(NH3)2(CBDCA-O)(H2O)]+, 3, which has nonequivalent
ammonia molecules. By comparison with 15N chemical shift
data for cis-[Pt(NH3)2(CBDCA-O)Cl]- (9) and a Pt2+ compound
containing a bound acetate ligand (22), the peak at 4.26/-82.3
is N trans to O (CBDCA), 3a, while the peak at 4.31/-87.8 is
assigned to N trans to O (H2O), 3b. The peak at 4.50/-86.5,
observed at later times, which has an 15N chemical shift similar
to that of 3b, has been assigned to cis-[Pt(NH3)2(H2O)2]+2, 4
(23). (Peak assignments are summarized in Table 1.) The
presence of this complex was also shown by earlier studies,
which employed UV-visible spectroscopy to measure the
kinetics of acid hydrolysis of carboplatin (24).

δ (1H)

δ (15N)

trans ligand

4.17
4.26
4.31
4.50
3.93
3.61
3.93
4.12
3.99
3.86

-81.3
-82.3
-87.8
-86.5
-82.3
-79.2
-84.3
-68.7
-83.3
-79.2

(O)CBDCA
(O)CBDCA
(O)H2O
(O)H2O
(O)CBDCA
(O)CO3-2
(O)CBDCA
Cl(O)CBDCA
(O)HPO4-2

a Mixture of 5, 6, and possibly 7 at pH 8.6. b The observed chemical
shift parameters at pH 7.5 are 3.94/-82.5 and 3.64/-79.6. c Ref 9.
d Protonation state and number of bound phosphate ligands not determined;
ref 9.

Further evidence that the initially formed product in the
hydrolysis reaction is the ring-opened complex was obtained
by changing the pH of the solution. As shown in Figure 2b,c,
when the pH is raised to 2.2 by the addition of 10 M KOH, the
peaks for 3 disappear and the peak for 1 intensifies. Thus, the
deprotonation of the unbound carboxyl group of 3 induces ring
closure, producing more 1, and that 3 indeed has an attached
mono-dentate CBDCA ligand. In Figure 2c, peak intensities
have been converted to concentrations, using the sum of the
peak intensities for 3a,b to obtain the concentration of the
monoaquo species 3. The concentration of carboplatin, species
1, decreases with time (linear fit shown in Figure 2c) until base
is added at 1.8 h, after which it increases. For t < 1.8 h, the
concentration of 3 increases at about the same rate as the
concentration of species 1 decreases; after 1.8 h, it decreases
rapidly to below the detection limit of the NMR measurement,
confirming that 3 forms from 1 in acid solution (ring opening),
and 3 can be converted to 1 (ring closing) if the pH is raised.
The concentration of the diaquo species 4 increases slowly with
time throughout the entire time period indicating that, while
most of 3 returns to 1, additional 4 also forms.
The reaction of 1 in 23.8 mM carbonate buffer (pH 8.6)
results in the slow decrease in the intensity of the peak for 1
(kinetics discussed below) and the appearance of two new peaks
at 1H/15N, δ ) 3.93/-82.3 and 3.61/-79.2 (Figure 3a). Because
the intensities of both product peaks increase at the same rate
and their 15N chemical shifts are consistent with N trans to O
(22), the carboplatin product that forms in carbonate buffer has
been assigned to the ring-opened complex, cis-[Pt(NH3)2(CO3-2)(CBDCA-O)]-2, 5 (Scheme 2). However, as discussed
below, this compound is in a proton equilibrium with its
protonated bicarbonate form, 6, and possibly also its decarboxylated hydroxo analogue, 7 (13, 15, 16, 25). By comparison
with the 15N chemical shift parameters of cis-[Pt(NH3)2(CBDCA-O)Cl]- (9), an acetato complex (22), and 3, the peak
at 1H/15N, δ ) 3.93/-82.3 in Figure 3a, is N trans to O
(CBDCA), 5a, while the peak at 1H/15N, δ ) 3.61/-79.2, has
been assigned to N trans to O (CO3-2), 5b. When the pH of the
23.8 mM carbonate buffer is lowered to 7.5, the rate of
conversion of 1 to the ring-opened product is reduced and 5
can only be detected after ∼18 h. Because lowering the pH
from 8.6 to 7.5 would lower the concentration of carbonate ion,
which is the attacking nucleophile in the reaction, a reduction
in the rate of formation of 5 at lower pH is expected. In addition
to slowing the reaction, lowered pH also results in protonation
of the bound carbonate to bicarbonate (Scheme 2). The resulting
bicarbonato complex could spontaneously decarboxylate to the
corresponding hydroxo form, 7, or it could retain the bound
bicarbonate (13, 15, 16, 25). As will be evident below, the UV
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Figure 2. (a) [1H,15N] HSQC NMR spectra of 220 µM 15N-carboplatin
1.3 h after the addition of 0.03 M HClO4 (t ) 1.3 h). Asterisks show
the 195Pt satellites of 1. At t ) 1.8 h, 10 M KOH was added to the
solution in part a to adjust the pH to 2.2. (b) HSQC NMR of solution
at pH 2.2 at t ) 3 h. Asterisks show the 195Pt satellites of 1. (c)
Concentrations of 15N-carboplatin species (original concentration, 220
µM) as functions of time, derived from HSQC NMR intensities in
solution. The solution was originally 0.03 M HClO4; addition of KOH
at 1.8 h changed the pH to 2.2. Diamonds and solid line, carboplatin;
triangles and dashed line, cis-[Pt(NH3)2(CBDCA-O)(H2O)]+ (the sum
of the intensities for both nonequivalent ammonia peaks is used); and
circles and gray line, cis-[Pt(NH3)2(H2O)2]+2. Lines are linear fits to
the first five points.

absorption studies show that the apparent pKb for the protonation
of 5 is ∼8.6, so, at pH 7.5, the ring-opened product exists as a
mixture of 5, 6, and possibly 7, which are in rapid equilibrium
with each other on the NMR time scale.
UV-Visible Absorption Studies. The absorption spectrum
of 500 µM carboplatin in 23.8 mM carbonate buffer, pH 7.5, is
shown in Figure 4. The compound exhibits a strong band at
203 nm (M ) 4600 M-1 cm-1) and a shoulder at 229 nm (M
) 2300 M-1 cm-1), which because of their intensities appear
to be charge-transfer transitions (3). The compound also exhibits
a much weaker band at 330 nm (M ) 40 M-1 cm-1), which
appears to be due to the d-d transitions of the square planar
Pt2+ ion. After several hours in carbonate buffer, carboplatin

Di Pasqua et al.

Figure 3. [1H,15N] HSQC NMR spectra of 110 µM 15N-carboplatin
in 23.8 mM carbonate solution. (a) pH 8.6, t ) 15.6 h; (b) pH 7.5, t )
18.6 h.

Figure 4. Absorption spectrum of 500 µM carboplatin in 23.8 mM
carbonate buffer, pH 7.5.

exhibits small but reproducible spectral changes indicating that
some of the drug has reacted with carbonate.
Figure 5, left side, shows difference spectra for the wavelength region, λ ) 200-300 nm, at five values of pH (6.7, 7.5,
8.1, 8.6, and 9.3) for the reaction of 500 µM 1 in 23.8 mM
carbonate buffer. Each graph shows difference spectra for the
times t ) 6, 12, 18, 24, and 30 h. The difference spectrum at

Carboplatin Carbonato Complexes
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Scheme 2. Ring Opening of Carboplatin by Carbonate Ion

time t is obtained by subtracting the absorption spectrum at time
0 from the absorption spectrum at time t. There is considerable
noise in a difference spectrum because the two spectra being
subtracted are very similar so that their difference is much
smaller than either. For clarity, we have shown in Figure 5 the
fits of the difference spectra to a sum of Gaussian bands (left
panel). The areas of individual bands as a function of reaction
time are also shown (right panel).
In each case, there is a relatively narrow peak at about 210
nm and a small broader peak at about 270 nm. For pH 6.7 and
pH 7.5, there is another peak between 215 and 225 nm. For pH
8.1, pH 8.6, and pH 9.3, there is a negative peak at about 239
nm. Linear fits have been made to peak areas vs time and are
shown on the right side of Figure 5.
In all cases, the areas of the peak near 210 nm are well-fit to
linear functions of time, R2 g 0.910. At pH 6.7, the areas for
the peak at 215-225 nm are fit (R2 ) 0.992) to a linear function
of time, -0.0998 + 0.0448t. For the peak near 270 nm, only
the area for the 3 minus 0 difference spectra was measurable.
At pH 7.5, the areas for the peak at 215-225 nm are fit (R2 )
0.933) to 0.133 + 0.023t, and the areas for the peak at 270 are
fit (R2 ) 0.841) to 0.0945 + 0.0131t.
The negative peak for pH 8.1 and higher, appearing at 239
nm, must arise from the depletion of carboplatin, since carboplatin exhibits an absorption at ∼230 nm (Figures 4 and 5).
When the areas of this peak at pH 8.1 are fit to a linear function
of time, -0.0942 + 0.0019t, the R2 ) 0.454. Thus, the value
of the slope is very uncertain. The same is true for the broad
peak near 270 nm, for which peak areas were only measurable
for eight out of 10 difference spectra.
At pH 8.6, the negative peak near 239 nm is much more
pronounced than it is at pH 8.1. This suggests that the rate of
disappearance of carboplatin increases with increasing pH. The
areas of the 239 nm peak are fit (R2 ) 0.974) to -0.2085 0.0159t. At pH 9.3, the peak at 239 nm grows even more
negative. The areas of the 239 nm peak are well-fit (R2 ) 0.938)
to a linear function of time, -0.7042 - 0.1129t.
In the cases where peak areas can be measured reliably from
the UV difference spectra, it is found that ratios of peak areas
are constant in time. For example, the ratio of the areas of the
peaks at pH 6.7 is 0.47 ( 0.07 (average ( standard deviation),
and at pH 7.5, the ratio of the sum of the areas of the highenergy peaks to the area of the 270 nm peak is 2.4 ( 0.2. The
constancy of a peak ratio implies either that both peaks come
from the same product or, if they come from different products,
that the products are produced simultaneously from the same

reactant. (If one product is transformed into the other by a rapid
proton exchange, it is equivalent to simultaneous production.)
At pH 8.6, the ratio of the 210 nm peak to the 270 nm peak is
4.0 ( 0.4 and the ratio of the 210 nm peak to the 239 nm peak
is -3.0 ( 0.2. The latter implies that the species giving rise to
the 210 nm peak arises from the species whose depletion is
responsible for the negative peak at 239 nm (carboplatin).
Determination of the pKb for the 5 to 6 Equilibrium. From
the UV-visible results, it is clear that, depending on pH, ring
opening produces one of two products. The products are likely
a carbonate adduct (5) at high pH and a bicarbonate adduct (6)
at low pH. The latter may decarboxylate to the corresponding
hydroxo form (7), with different UV absorption peaks. Because
5 differs from 6 by loss of a proton, it is of interest to determine
the pKb of 5. Normally, this would be done by plotting
absorption intensity for a given wavelength, taken from a
difference plot, vs pH, with all difference plots being obtained
at the same t. In the present case, however, one must take into
account the pH dependence of the rate of the ring-opening
reaction. From the rate of decrease of the carboplatin peak
intensity in NMR, one can find the first-order rate constant k1
for this reaction (see Table 2). A plot of log k1 vs pH for 10
mM carbonate is well-fit by log k1 ) -9.25 + 0.422 pH, and,
for 23.8 mM carbonate, log k1 ) -8.54 + 0.363 pH. This
predicts that the ratios of the rates at pH 7.5, 8.1, 8.6, and 9.3
to the rate at pH 6.7 are approximately 2.1, 3.5, 5.6, and 10.5,
respectively. So, if one compares absorption intensities for
different pH values at some fixed wavelength, one should
compare the 30 h difference spectrum for pH 6.7 with the 14 h
difference spectrum for pH 7.5, the 9 h difference spectrum for
pH 8.1, the 5 h difference spectrum for pH 8.6, and the 3 h
difference spectrum for pH 9.3.
Absorbances were obtained from the difference spectra for
each of the above times for 12 different wavelengths ranging
from 210 to 240 nm. Each set of data, corresponding to a
specific wavelength, was fit to a titration curve using Excel
Solver, giving a Kb value of ∼8.6. The corresponding pKa for
deprotonation of 5 is 5.4.
Reaction of 1 in Different Media. Figure 6 shows carboplatin concentrations, obtained from HSQC NMR intensities,
as functions of time for three 110 µM solutions, with leastsquares linear fits. The three solutions were carboplatin in water
at pH 7.5, carboplatin in 10 mM carbonate buffer at pH 8.6,
and carboplatin in 23.8 mM carbonate buffer at pH 8.6. Figure
7 shows similar information for three 110 µM solutions
containing different cell growth media conditions. These were
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Figure 5. Shown in the left panel are UV-visible difference spectra at pH 6.7, 7.5, 8.1, 8.6, and 9.3. Each plot shows the difference between the
spectra at times t ) 30 (top difference curve at 210 nm), 24, 18, 12, and 6 h (bottom difference curve at 210 nm) and the spectrum at t ) 0 h. For
clarity, the fit to a sum of Gaussians is shown rather than the original experimental data, which shows considerable scatter. Shown in the right panel
are peak areas plotted vs time, with linear fits to the data. The peak at 210 nm is diamonds and solid line; the peak at 215-225 nm for pH 6.7 and
pH 7.5 and at 239 nm for pH g 8.1 is squares and large dash line; and the peak at 270 nm is triangles and small dash line.
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Table 2. Pseudo-First-Order Rate Constants for the Reaction of
Carboplatin in Various Media Obtained Using HSQC NMR

water, pH 7.5
10 mM carbonate, pH 6.7
23.8 mM carbonate, pH 6.7
10 mM carbonate, pH 7.5
23.8 mM carbonate, pH 7.5
10 mM carbonate, pH 8.6
23.8 mM carbonate, pH 8.6
normal mediuma
medium minus carbonatea
FBS, pH 7.5
with Jurkat cells
140 mM chloride, pH 7b
100 mM phosphate, pH 7b

k1 (s-1)

standard error

5.09 × 10-7
3.88 × 10-7
6.54 × 10-7
7.87 × 10-7
2.04 × 10-6
2.44 × 10-6
3.36 × 10-6
3.08 × 10-6
2.25 × 10-6
1.79 × 10-6
2.82 × 10-6
7.7 × 10-7
4.3 × 10-7

4.01 × 10-7
6.39 × 10-7
3.30 × 10-7
3.28 × 10-7
8.10 × 10-7
1.31 × 10-6
3.10 × 10-7
2.02 × 10-7
2.52 × 10-7
1.77 × 10-7
5.94 × 10-7
2.0 × 10-8

a See Materials and Methods for complete description of media and
conditions. b Ref 9.

Figure 6. Concentration of 15N-carboplatin (original concentration,
110 µM) as a function of time derived from HSQC NMR intensities,
with linear fits to the data. Carboplatin in water at initial pH 7.5 is
squares and dashed line; carboplatin in 10 mM carbonate buffer at pH
8.6 is triangles and solid line; and carboplatin in 23.8 mM carbonate
buffer at pH 8.6 is diamonds and gray line.

Figure 7. Concentration of 15N carboplatin in media (original
concentration, 110 µM) as a function of time, derived from HSQC NMR
intensities, with linear fits to the data. Carboplatin in medium is squares
and solid line; carboplatin in medium minus carbonate is diamonds
and gray line; and carboplatin in medium with Jurkat cells is triangles
and dashed line. See Materials and Methods for complete description
of media and conditions.

the following: normal medium, RPMI + 10% FBS; normal
medium without carbonate, RPMI + 10% FBS minus NaHCO3;
and normal medium exposed to Jurkat cells. In both Figures 6
and 7, HSQC peak intensities have been converted to concentrations by performing a least-squares linear fit, obtaining the
y-intercept I0, and multiplying all intensities by (110 µM)/I0.
In Figure 6, the top line is for water at pH 7.5, the second
line is for 10 mM carbonate at pH 8.6, and the bottom line is
for 23.8 mM carbonate at pH 8.6. Because of increased scatter
in the data, only 14 (instead of 20) data points were used for

Figure 8. Pseudo-first-order rate constants derived from decay rate
of the 1H-15N HSQC NMR peak for 15N-carboplatin, with statistical
errors from linear fits. Key: 1, in water at pH 7.5; 2, in 10 mM
carbonate at pH 6.7; 3, in 23.8 mM carbonate at pH 6.7; 4, in 10 mM
carbonate at pH 7.5; 5, in 23.8 mM carbonate at pH 7.5; 6, in 10 mM
carbonate at pH 8.6; 7, in 23.8 mM carbonate at pH 8.6; 8, in “medium”;
9, in “medium minus carbonate”; 10, in “FBS alone”; and 11, in
“medium with Jurkat cells”. See Materials and Methods for the
definitions of the terms in quotations.

the 10 mM carbonate run. It can be seen that k1 is close to zero
for water but appreciable for the two carbonate solutions. In
fact, at pH 6.7, 7.5, and 8.6, k1 for 23.8 mM carbonate is, on
average, twice the k1 for 10 mM carbonate. This concentration
dependence suggests that attack of a species in carbonate buffer
(most likely carbonate ion) is responsible for the ring opening,
which removes carboplatin. In Figure 7, the top line is for 110
µM carboplatin in medium without carbonate at a pH of 7.5,
the bottom line is for carboplatin in normal medium, and the
middle line is for carboplatin in medium exposed to Jurkat cells.
The three slopes are fairly close together, but the slope for
normal medium is ∼1.5 that for medium without carbonate.
This confirms that carbonate in the medium is responsible for
the reaction that converts carboplatin to products. The rate of
decrease of carboplatin in medium exposed to Jurkat cells is
about the same as that in normal medium not exposed to cells.
This shows that Jurkat cells have no effect on the ability of
substances in the medium (carbonate) to decrease the concentration of 1. In none of the studies involving culture media (and
FBS alone), which were done at pH 7.2-7.5, were HSQC NMR
peaks for products observed. This is most likely due to the fact
that the rate of ring opening slows when the pH is lowered and
a small amount of product would be difficult to detect with the
NMR instrumentation used.
By dividing the slope of a linear fit by the y intercept, one
obtains the pseudo-first-order decay constant k1 for the disappearance of carboplatin. Note that although the ring-opening
reaction is really second-order (first-order in both carbonate and
carboplatin), it behaves like a first-order reaction because
carbonate is not consumed in the reaction. The values obtained
for k1 are given in Table 2, with the statistical errors from the
linear fits, and are also plotted in Figure 8 for easier visual
comparison.
If carbonate is the attacking reagent, k1 should be proportional
to [CO32-], the concentration of carbonate ion. This can be
calculated for a given pH and total carbonate concentration,
since the equilibrium constants

K1 )
and

[HCO3-][H+]
[CO2]
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[CO32-][H+]
[HCO3-]

are known as: K1 ) 9.33 × 10-7, pK1 ) 6.35; and K2 ) 1.59
× 10-10, pK2 ) 10.33 (26). The total carbonate concentration
is [CO2] + [H2CO3] + [HCO3-] + [CO32-]; note that [H2CO3]
is negligibly small (25, 26).
The proportionality to carbonate concentration at fixed pH
has already been demonstrated. In Figure 9, six values of k1
are plotted vs [CO32-], calculated as above, on a semilog plot
for clarity. The k1 values were determined from the observed
rates from the HSQC NMR data (Table 2 and Figure 8) for
23.8 and 10 mM carbonate at pH 6.7, 7.5, and 8.6. The statistical
errors associated with linear fits of the data, shown in Figure 9,
are large, which is not unexpected, given the difficulty in
measuring accurate rate constants at the low concentrations of
carboplatin used. The best-fit line, also shown, is k1 ) 9.3 ×
10-7 + 0.00612 [CO32-] (R2 ) 0.79), the small value of R2
being due to the scatter in the k1 values. Considering that the
independent variable [CO32-] ranges over 3 orders of magnitude,
the fit is quite satisfactory.

Discussion
As is evident from Table 2 and Figure 8, increasing the pH
at a constant total carbonate concentration or increasing the total
carbonate concentration at a constant pH leads to an increase
in the rate of reaction of 1 in carbonate buffer. The k1 values
for 10 mM carbonate at three pH values follow log (k1) ) -9.25
+ 0.422 pH (R2 ) 0.998), and the k1 values for 23.8 mM
carbonate obey log (k1) ) -8.54 + 0.363 pH (R2 ) 0.901).
Also, the ratio of k1 for 23.8 mM carbonate to k1 for 10 mM
carbonate is equal to 1.7, 2.6, and 1.4 for pH ) 6.7, 7.5, and
8.6, respectively. Because the actual concentration of carbonate
ion increases when either total carbonate or pH increases (13),
the attacking nucleophile in the ring-opening reaction of
carboplatin is carbonate ion. This is confirmed by plotting k1
vs [CO32-] (see Figure 9) and showing the data fit the linear
function, k1 ) 9.3 × 10-7 s-1 + 6.1 × 10-3 s-1 M-1 [CO32-].
Sadler and co-workers (9) obtained pseudo-first-order rate
constants for reaction of carboplatin in 140 mM chloride and
100 mM phosphate, pH 7.0, 37 °C, of 7.7 × 10-7 and 4.3 ×
10-7 s-1, respectively. Because the pseudo-first-order rate
constant for the reaction of carboplatin in 23.8 mM carbonate,
pH 7.5, 37 °C, is much larger (2.04 × 10-6, Table 2), carbonate
ion is probably the nucleophile activating carboplatin (opening
the ring) in vivo. This conclusion is also supported by the
observed rates of disappearance of carboplatin in medium in
the presence and absence of carbonate (Table 2 and Figure 7).
Sadler and co-workers (9) measured the pseudo-first-order
rate constant for the hydrolysis of carboplatin in water. Because
they were unable to detect changes in the 1H NMR spectra of
the compound after 2 weeks at 37 °C, pH 7, they reported a
value of k1 for the hydrolysis of <5 × 10-9 s-1, which was
consistent with an earlier study by Canovese et al. (4), which
suggested that k1 is <1 × 10-8 s-1. As is evident from Table
2, the rate constant for the reaction of carboplatin in water
measured by HSQC NMR in this study is (5.09 ( 4.01) × 10-7
s-1, pH 7.5, which is significantly larger than that found in the
earlier studies. Because our study was done using a low
concentration of carboplatin (110 µM) and the pH was not
controlled (no buffer was added), it may be that changes in pH,
occurring as the reaction takes place, influence the rate of

Figure 9. Observed rate constant for the disappearance of carboplatin
obtained from HSQC NMR data plotted vs true carbonate concentration.
The best-fit line, R2 ) 0.79, is k1 ) 9.3 × 10-7 + 0.00612 [CO32-].

disappearance of 1 during the 20 h NMR experiment. Significant
variations in measured hydrolysis rates for 1 in unbuffered media
have been previously reported (9, 27).
As shown in Scheme 2, the initially formed mono-carbonato
complex 5 can be protonated to form the mono-dentate
bicarbonato complex, 6. Because the pKb for the protonation
of 5 determined from the UV-visible absorption data is ∼8.6,
the compound is partially protonated (as 6) at physiological pH.
Evidence from the literature suggests that 6 could remain as a
mono-dentate bicarbonato complex, or it could decarboxylate
to the hydroxo complex, 7 (13, 15, 16, 25). A mono-dentate
bicarbonato-zinc complex is believed to be important in the
dehydration of HCO3- catalyzed by human carbonic anhydrase
II (28, 29), and a similar species could be among the ring-opened
products for carboplatin. Thus, at physiological pH, compound
5 appears to be in equilibrium with 6 and possibly also its
decarboxylated hydroxo form, 7. Even though the unbound
carboxylate of the CBDCA ligand is deprotonated at physiological pH and it could presumably attack the Pt to reform
carboplatin, ring closure for 5-7 does not occur. Most likely,
this is due to the poor leaving groups in cis positions (anions),
which would need to be displaced in the closure reaction. As
shown in Scheme 1 and Figure 2, if the group cis to the monodentate CBDCA ligand is H2O, which is generated in the acid
hydrolysis of 1, release of the proton from the unbound
carboxylate results in water displacement from Pt and ring
closure to reform carboplatin.
The UV-visible difference spectra show that the nature of
the ring-opened product formed in 23.8 mM carbonate buffer
depends on pH (Figure 5). At pH 9.3, the negative band at 239
nm increases with time more rapidly than at pH 8.6 and much
more rapidly than at pH 8.1, indicating that the concentration
of compound 1 is decreasing and that the mixture of products
has a relatively weak absorption at this wavelength. At pH 6.7,
or at pH 7.5, the band at 215-225 nm becomes strongly positive
and grows with time, indicating that the product predominantly
formed at lower pH has a strong absorption at this wavelength.
Mahal and van Eldik (15) have reported that a CT band near
260 nm (the absorption maximum was not reported) for a series
of Pd(II) complexes having mono-dentate carbonate decreases
in intensity as pH is lowered. The decrease in intensity was
attributed to the elimination of intramolecular hydrogen bonding
between the bound carbonate and an adjacent amine hydrogen
of the complex as the carbonate ligand is destroyed by acid.
As is evident from Figure 5, lowering the pH leads to an increase
in intensity in this region. However, because 5 has two ligands,
CO32- and CBDCA, which can potentially form intramolecular
hydrogen bonds with adjacent amine hydrogen atoms, the effects
of pH on the CT transition of the ring-opened products are
difficult to predict.

Carboplatin Carbonato Complexes

As is evident from Table 2, the NMR peak for carboplatin
disappears at approximately the same rate in culture media and
23.8 mM carbonate, implying that carbonate is the attacking
nucleophile, and the reaction shown in Scheme 2 takes place.
However, ring-opened products are not detected with HSQC
NMR in culture media. This contrasts with what is found with
cisplatin, which rapidly reacts with carbonate in culture media
to produce amounts of cis-[Pt(NH3)2(CO3-2)Cl]- readily detected with HSQC NMR (18, 19). The reason for no observation
of product peaks in the 20 h NMR experiment for carboplatin
probably relates to the mechanism of formation of carbonato
complexes for cisplatin and carboplatin in carbonate media. For
cisplatin, aquation occurs much more rapidly than with carboplatin, to produce cis-[Pt(NH3)2(H2O)Cl]+ and cis-Pt(NH3)2(OH)Cl, which, at pH 7.4, are in a rapid proton equilibrium
with one another. While both of these compounds can potentially
react with components in media to produce carbonato species,
the mono-hydroxo complex probably reacts with dissolved
carbon dioxide within milliseconds (26) to give the monocarbonato compound, cis-[Pt(NH3)2(CO3-2)Cl]- (18, 19). The
reaction is rapid because reaction of CO2 with a hydroxo ligand
does not require a metal-ligand bond-breaking step, which
would be slow. For cisplatin, the initial amount of mono-aquo
complex present in the clinical formulation, and the rapid rate
of production of more mono-aquo complex from the dichloro
compound, allow cis-[Pt(NH3)2(CO3-2)Cl]- to rapidly build up
and persist in the HSQC NMR spectrum in culture media for
20 h. The hydrolysis rate of carboplatin is much slower than
that of cisplatin, so formation of a carbonato complex by reaction
of carbon dioxide with a hydroxo species is not possible. As
outlined above, compound 5 forms by the attack of carbonate ion on carboplatin, which is much slower than the
route used by cisplatin to form a carbonato complex. Thus,
the carboplatin ring-opened product is slow to form in culture
media, making detection of the product by HSQC NMR
difficult.
We have shown that, at physiological pH, 1 reacts with
carbonate ion at concentrations found in culture media and blood
to produce a small amount of ring-opened products, all of which
are anions. If produced under conditions of therapy, they could
be taken up by cells and distributed to various organs of the
body. In the studies done in the presence of a high density of
Jurkat cells, the rate of disappearance of carboplatin in media
was the same as that in media without cells or in 23.8 mM
carbonate buffer (pH 8.6) (Table 2 and Figure 8). Thus, the
cells do not significantly affect the reaction of the medium with
carboplatin, from which we infer that carbonate in the medium
is mainly responsible for the disappearance of 1 even when cells
are present. As expected, continued exposure of Jurkat cells to
carboplatin results in significant loss of cell viability and after
6 h a significant fraction of the population has died.
An important parameter in the administration of Pt drugs to
patients is the AUC, which is the product of the exposure time
to the drug and the concentration of the drug in the extracellular
fluid (30, 31). In calculating AUC, attention is not normally
paid to what forms of the drug are present in the extracellular
fluid but only to the total Pt content. It seems more appropriate
to use the extracellular concentrations of the forms of the drug
that are taken up by the cell and responsible for the antitumor
effects. Although the rate of reaction of carboplatin with
carbonate is about 2 orders of magnitude slower than the
corresponding rate for cisplatin with carbonate (18, 19), the
elimination rate of 1 from the body is significantly slower than
that of cisplatin (32, 33). Combined with the fact that the
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concentration of 1 normally used in therapy is an order of
magnitude greater than that of cisplatin (32, 33), this may mean
that, in terms of carbonato complexes (which may be the species
entering the cell and producing the cytotoxic effects), AUC
values could be similar for 1 and 2. To what extent the AUC
values of the carbonato complexes of carboplatin and cisplatin
in cell culture studies and therapy correlate with the toxicity
and antitumor effects of these drugs will require further
investigation.
In the commonly accepted mechanism of action of
cisplatin, the drug enters the cell as the dichloro form, which,
because the chloride concentration inside the cell is low, aquates
to produce the more reactive mono-aquo complex (34, 35).
The latter reacts with many components of the cell, but its
interaction with DNA is believed to be the important event
leading to cell death (36). Recently, transport into the cell has
been shown to possibly involve trans membrane proteins and
direct binding to Pt (37, 38). The mechanism of action of
carboplatin has been less studied than that of cisplatin, but
carboplatin is believed to enter the cell either unmodified or
possibly modified in the extracellular fluid by some nucleophile
that displaces (opens) the CBDCA chelate ring. Like cisplatin,
carboplatin treatment leads to platination of DNA, suggesting
that the drugs have a common mechanism for the induction of
apoptosis (39).
Relevant to the cytotoxic effects of Pt-carbonato complexes
are the reaction conditions existing in the blood and cytosol.
The intracellular concentration of carbonate for cells carrying
out normal metabolism is approximately the same as that in
blood, ∼24 mM (14), so Pt-carbonato complexes could be
stable in plasma and, once inside the cell, also in the cytosol. It
is well-known that thiols such as GSH inside the cell readily
react with Pt drugs, producing Pt-GSH adducts, with consequences that have been widely discussed (40). Although GSH
and other thiols are present in culture media, they seem to have
little effect on the survival of cis-[Pt(NH3)2(CO3-2)(Cl)]- in
media (18). As was earlier suggested, this could be because
thiols in media exist in disulfide form, which is less reactive
toward Pt. An additional factor may be that, because 5-7 and
cis-[Pt(NH3)2(CO3-2)(Cl)]- are anions, attack by a thiolate, also
an anion, is not favored, making the rate of Pt-S bond formation
slower (3). Thus, anionic Pt-carbonato species could have
longer than expected half-lives in plasma and the cytosol, giving
them more time to produce their biological effects. Work in
progress will determine if and to what extent the ring-opened
carboplatin compounds are toxic to cells.
A central question concerning the carbonates formed by
carboplatin and cisplatin is their potential to interact with nuclear
DNA. In 1984, Fichtinger-Shepman et al. (41) reported that 20
mM NaHCO3 reduces the amount of Pt bound to salmon sperm
DNA to ∼one-third of that found when no buffer is present in
the medium. Because cisplatin forms carbonato species in
carbonate buffer (18, 19), carbonato complexes can bind to
DNA. Although the parallel study for carboplatin has not been
reported, the results summarized in Scheme 2 suggest that
carboplatin would behave similarly to cisplatin and that carboplatin carbonato compounds could also bind to DNA.
Clearly, characterizing the forms of the Pt drugs existing in
biological media, the mechanisms by which they enter the cell,
and the cellular sites of action are critical for understanding the
antitumor effects and toxicities of these important drugs. We
hope that this report will stimulate interest in the role of
carbonate in the molecular mechanism of action of Pt anticancer
drugs.
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Conclusions
In this report, we show that carbonate ion at concentrations
found in culture medium and blood readily displaces one arm
of the CBDCA ligand of carboplatin to form a ring-opened
product having bound carbonate. Using UV-visible absorption
spectroscopy, we show that carboplatin reacts with carbonate
in the pH range of 6.7-9.3, with the rate of the reaction and
the nature of the product dependent on pH. Analysis of the UVvisible and NMR spectral data reveals that the compound formed
at slightly basic pH is a ring-opened product having monodentate carbonate. We also show that the pKb for protonation
of this species is ∼8.6, so that reaction of carboplatin with
carbonate at physiological pH produces a mixture of the
carbonato and bicarbonato ring-opened products and, because
the latter can spontaneously decarboxylate, the analogous
hydroxo species may be present as well. An important similarity
between cisplatin and carboplatin is that both drugs react with
biologically relevant concentrations of carbonate to give negatively charged species. Because molecular charge affects biodistribution and reactivity of compounds in vivo, the existence
of Pt-carbonato species under physiological conditions may
help explain the uptake, antitumor properties, and toxicities of
these important Pt drugs.
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